Skip to search formSkip to main contentSkip to account menu

enzastaurin

A substance being studied in the treatment of certain types of cancer, including non-Hodgkin lymphoma, breast, colon, lung, ovarian, and prostate… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Indoles

Narrower (1)

LY317615.HCl
enzastaurin hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
Highly Cited
2008
Highly Cited
2008
Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Activation of protein kinase C (PKC) has been implicated in gastric carcinogenesis. Enzastaurin is an oral ATP-competitive… 
Highly Cited
2008
Highly Cited
2008
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
PURPOSE Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses protein kinase C (PKC) and protein kinase B/AK… 
2008
2008
Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study
2005 Background: ENZ, an oral serine/threonine kinase inhibitor, targets PKC and AKT pathways to induce tumor cell apoptosis and… 
2008
2008
Enzastaurin‐induced apoptosis in glioma cells is caspase‐dependent and inhibited by BCL‐XL
The novel protein kinase C‐β inhibitor enzastaurin (ENZA) induced apoptosis in LNT‐229 and T98G cells whereas A172 cells were… 
Highly Cited
2007
Highly Cited
2007
Synergistic antiglioma activity of radiotherapy and enzastaurin
Radiotherapy is an essential treatment modality for malignant gliomas, but it exerts adverse effects via promotion of glioma cell… 
Review
2007
Review
2007
Enzastaurin, a Protein Kinase Cβ–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through protein kinase C (PKC)-β and the… 
2007
2007
Survival improvement in thoracic cancer: progress from the last decade and beyond.
Highly Cited
2006
Highly Cited
2006
Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines
Enzastaurin (LY317615), an acyclic bisindolylmaleimide, is an oral inhibitor of the protein kinase Cβ isozyme. The objective of… 
Review
2005
Review
2005
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)